Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Down sharply on average volume so far. Not a capitulation. The overall .market is down today, especially the nasdaq.
Ugh. Hit piece? There are end point results here I have not seen before.
https://endpts.com/neurorx-chief-lines-up-hail-mary-for-once-rejected-covid-19-drug/
I don't see this trial as meaningful with a study end date in August and trial results expected in September.
Seems Congress is getting ready to tax stock trades. That's a sure fire way to tank the market. Hope we get a resolution here soon but it might not matter. Prepare to pay for your trades even if they occur before a law is passed.
In his remarks Fauci mentioned therapies already available for mild covid symptoms but said we now need therapeutics for critical covid cases. Another bread crumb as far as I'm concerned.
I just bought more shares based on that update. Hoping for news soon.
Not much of an article to be honest.
Data has already been resubmitted for an eua by neurorx.
Price spiking on no news and average volume. Hmm, I've seen this movie before.
Heart Damage Found in More Than Half of COVID-19 Patients Discharged From Hospital
https://scitechdaily.com/heart-damage-found-in-more-than-half-of-covid-19-patients-discharged-from-hospital/
Early intervention with an effective therapeutic would go a long way towards preventing this damage I think.
How do we know what Cognate's annual revenue is? They're a private company. Do we have a number or just the CR estimate going forward?
Use politicians as guinea pigs for the trial although the trial would probably fail because it would be the equivalent of carrying coals to Newcastle.
Cognate has 12,000,000 shares of NWBO and a contract agreement to produce DCVax for clinical trials so there is potentially an impact on NWBO. Whether good, bad, or indifferent? Who knows.
Speculation on the board has been that cognate will be manufacturing DCVax for the US market after FDA approval. Link to a report on the purchase by Charles River.
https://www.pharmiweb.com/pwtoday-story/charles-river-laboratories-to-acquire-cognate-bioservices-to-create-a-premier-scientific-partner-for-cell-and-gene-therapy-development
According to the yahoo board Cognate is being acquired by Charles River. Tangentially related to NWBO.
A hit piece out on rlf100 this morning. If you're interested, it's instructive to read and see how it's done. Nothing new is said but it takes last week's news and implies a failure of the trial.
https://endpts.com/covid-19-roundup-who-all-but-confirms-virus-not-man-made-neurorx-relief-say-they-dont-know-if-iv-treatment-works/
It was just a passing thought. I was thinking maybe the virus is still active even after recovery. I would like to hear thoughts on that from some of the medical professionals here.
New study shows some COVID-19 patients end up with damage to brains
https://kstp.com/coronavirus/new-study-shows-some-covid-19-patients-end-up-with-damage-to-brains-february-15-2021/6014166/
I recall an earlier related discussion here suggesting the virus can cross the blood brain barrier as can rlf100. I wonder if rlf100 administered post recovery could help with the reported brain damage.
My greatest worry here is that the FDA is concentrating exclusively on vaccines. I hope we'll get approval in Europe but the trial is in the US and I don't know how the European agencies will deal with it.
I'm not able to read the article. Can you give a brief summary?
That was explained in the YouTube interview this morning. It's an old FDA requirement. The company didn't set that as their primary endpoint. The FDA did.
Phase 1 trial
Makes sense. Early patients are already past the 60 day mark and there will be more as we go along. They will have a good idea of the 60 day results before Feb 20.
ETA: I dont expect spectacular results. We may not even hit stat sig. Decreased Mortality in a small group trial is extremely difficult to prove.
Swiss market up 13% (.04 cents) on very heavy volume. Looks like the market has digested the data and concluded it is good. We should get back some of yesterday's losses.
The hfnc data is intriguing. Presumably patients on hfnc were the most critical in this trial (medical professionals here correct me if I'm wrong about that) although not as far along as those in the open trial. It seems the sicker a patient is the more effective rlf100 is. I would hope that weighs in relief's favor with the FDA.
The FDA hasn't weighed in on the results yet.
Since remdesivir, along with other soc drugs, were administered in the trial and the rlf100 group fared better then it's definitely better than remdesivir.
There is a post on the yahoo board showing the drop off of survival starting about the 28 day mark for patients not treated with rlf100. The post compares it with rlf100 survival data from the open trial and the results are dramatic but there are caveats. The data is from the sickest patients, literally at deaths door. The results from the closed trial just released was for patients in less severe circumstances so the mortality rate overall will not be as great. Still, the data might show stat sig for 60 day mortality.
From what I'm reading elsewhere mortality increases beyond 28 days so maybe they'll find something useful in the data but you have to wonder why the set the primary end point at 28 days knowing that.
Your first link doesn't work. I do take your point though that the data should get better approaching 60 days. Which begs the question. Knowing that, why did they set the primary end point at 28 days?
Yes but it isn't spectacular. The big issue with today's results is it didn't meet its primary end point.
Recovery from the low continues on the Swiss exchange so hoping we will see a bounce back on the US side and it holds above .40.
18 now on the Swiss exchange. If I were a short here I would be popping the cork on some good champagne.
Over 50% down now and headed lower. We could possibly open here in the teens. This isn't a short squeeze. It's a capitulation.
Down 37% now. The Market says this is bad news.
Going below .40 today I expect. The news is not good.
Secondary endpoints only and p factor is not spectacular even if it shows significant benefit. Primary end point data not reported here.
Thanks. I appreciate the confirmation of the YouTube claim.